The internet talks about GLP-1 drugs as if they were one category with one outcome. That is not how the biology works. GLP-1 is a signaling hormone. Semaglutide, tirzepatide, and retatrutide are frequently collapsed into a single conversation, but their pathway profiles are not identical, and those differences are precisely what the underlying science is about.

A drug's mechanism shapes the study question. A single-pathway agonist gets researched, dosed, and compared differently from a dual agonist, which in turn gets studied differently from a triple agonist under active investigation. When public conversation flattens all of this into a single headline — usually the weight-loss one — it loses the frame that makes any of it interpretable.

This article walks the pathway logic without treating any compound as a shortcut, a trend, or a lifestyle hack. It is not medical advice. It is a reading guide for the science.

The FDA-approved labeling for semaglutide describes it as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor — the same receptor targeted by the endogenous hormone.[2] Structurally it is an acylated peptide engineered for a long circulating half-life; mechanistically it is a single-pathway compound centered entirely on GLP-1 receptor signaling.

Public coverage tends to compress semaglutide into "a weight-loss drug." The compression is not wrong so much as incomplete. Mechanistically it belongs in a broader conversation about incretin biology: glycemic regulation, gastric motility, appetite signaling, and the clinical trial design used to measure any of those things. Reading it only through the weight-loss frame loses the reason it works the way it does.

Nothing in this section is a recommendation. Semaglutide is a prescription medication, dispensed and monitored inside the standard clinical system. The point here is only the pathway profile — because that is what changes when we move to the next compound.

Tirzepatide is described in pharmacology references as a dual agonist of the GIP and GLP-1 receptors — a single peptide that engages two incretin-related receptor systems simultaneously.[3] That distinction is why the scientific conversation around tirzepatide is not simply "another GLP-1." The molecule is doing two things at the receptor level, and study designs comparing it to single-pathway agonists are structured around that difference.

GIP — glucose-dependent insulinotropic polypeptide — is itself an incretin, but it is not interchangeable with GLP-1. The two hormones activate different receptors, are secreted from different cell populations, and are studied with distinct downstream effects on insulin release, adipose tissue biology, and metabolic signaling. Combining them in one molecule changes the pharmacology being measured, not just its intensity.

The common shortcut — "tirzepatide is a stronger version of semaglutide" — collapses this distinction into a linear scale that the underlying biology does not support. A dual agonist is a different research question, not the same question turned up. Where the literature reports differences, the more accurate framing is that a wider receptor profile was tested, not that one drug is uniformly better than the other.

Retatrutide has been studied as a triple agonist of the GIP, GLP-1, and glucagon receptors. A phase 2 trial published in The New England Journal of Medicine evaluated retatrutide in adults with obesity and reported substantial body-weight reductions over 48 weeks.[4] The compound is investigational; it does not carry an FDA approval for the indications typically discussed online, and the ongoing phase 3 program will determine what, if anything, the regulator ultimately concludes.

The mechanistic point is what makes retatrutide interesting on this page. Adding glucagon receptor activity to a GIP/GLP-1 backbone changes the pathway conversation again — glucagon signaling touches hepatic glucose output, lipolysis, and energy expenditure in ways that are distinct from anything a pure incretin agonist is doing.[5] The study question is not "how much weight loss" but "what happens when three hormone-receptor systems are engaged by one molecule."

Investigational should be read literally. It means researchers are still measuring, and the risk-benefit profile is still being defined. The compound is a live research object, not a consumer product, and any framing that presents it as the next lifestyle shortcut is running ahead of what the record actually shows.